Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
2.380
+0.100 (4.39%)
At close: Apr 25, 2025, 4:00 PM
2.370
-0.010 (-0.42%)
After-hours: Apr 25, 2025, 6:42 PM EDT
Akebia Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Akebia Therapeutics stock have an average target of 6.50, with a low estimate of 6.00 and a high estimate of 7.50. The average target predicts an increase of 173.11% from the current stock price of 2.38.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Akebia Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 1 | 2 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 1 | 1 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +215.13% | Apr 4, 2025 |
| Jefferies | Jefferies | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +152.10% | Apr 1, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $4 → $6 | Buy | Maintains | $4 → $6 | +152.10% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +215.13% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +215.13% | Jan 23, 2025 |
Financial Forecast
Revenue This Year
196.22M
from 160.18M
Increased by 22.50%
Revenue Next Year
281.05M
from 196.22M
Increased by 43.23%
EPS This Year
-0.20
from -0.33
EPS Next Year
-0.02
from -0.20
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 235.7M | 383.6M | 462.2M | ||
| Avg | 196.2M | 281.1M | 371.8M | ||
| Low | 173.4M | 208.3M | 262.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 47.1% | 95.5% | 64.5% | ||
| Avg | 22.5% | 43.2% | 32.3% | ||
| Low | 8.2% | 6.1% | -6.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.06 | 0.35 | 0.37 | ||
| Avg | -0.20 | -0.02 | 0.15 | ||
| Low | -0.35 | -0.21 | -0.22 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.